首页> 外文期刊>The Journal of toxicological sciences >Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis
【24h】

Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis

机译:利用人诱导的多能干细胞衍生心肌细胞和基因表达分析评估药物的心律源潜力评估系统

获取原文
获取原文并翻译 | 示例
       

摘要

In recent years, human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) have been widely used to develop evaluation systems for drug cardiotoxicity, including the arrhythmia caused by QT prolongation. To accurately assess the arrhythmogenic potential of drugs, associated with QT prolongation, we developed an evaluation system using hiPS-CMs and gene expression analysis. hiPS-CMs were treated with 8 arrhythmogenic and 17 non-arrhythmogenic drugs at several concentrations for 24 hr to comprehensively analyze gene expression. The results showed that 19 genes were upregulated in the arrhythmogenic drug-treated cells compared with their expression levels in the non treated and non-arrhythmogenic drug-treated cells. The arrhythmogenic risks of the drugs were evaluated by scoring gene expression levels. The results indicated that arrhythmogenic risks could be inferred when cells were treated at a concentration 100 times higher than the maximum blood concentration of the drug. Thus, we succeeded in developing a system for evaluation of the arrhythmogenic potential of drugs using gene expression analysis.
机译:近年来,人诱导的多能干细胞衍生的心肌细胞(HIPS-CMS)已被广泛用于开发用于药物心脏毒性的评估系统,包括QT延长引起的心律失常。为了准确评估药物的心血性潜力,与QT延长相关,我们使用髋关节和基因表达分析开发了评估系统。用8个心律发生和17个非心性发育药物处理HIPS-CMS,以几种浓度进行24小时,以全面分析基因表达。结果表明,与未治疗的非治疗和非心律失常药物处理细胞中的表达水平相比,在心律源药物处理细胞中上调了19个基因。通过评分基因表达水平评估药物的血糖性风险。结果表明,当在比药物的最大血液浓度高100倍的浓度下处理细胞时,可以推断出血管发育风险。因此,我们在使用基因表达分析中成功地开发了用于评估药物的心律源潜力的系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号